Main Article Content
Gliomas are the primary brain tumors of the central nervous system. They arise from the glial and other cells and are categorized into 1) astrocytomas, including astrocytoma, anaplastic astrocytoma and glioblastoma, 2) ependymomas, including anaplastic ependymoma, myxopapillary ependymoma and subependymoma, and 3) oligodendrogliomas, including anaplastic oligodendroglioma and oligoastrocytoma. The prognosis, especially for high-grade gliomas, is dismal; the treatment of these tumors represents an unmet need in medicine. More patients die from malignant gliomas than, for example, from melanoma. Unlike for low-grade glioma, modest progress has been made in the treatment of these tumors during the last several decades. In this book several critical issues pertinent to the understanding and treating gliomas are discussed. The need for more clinically relevant models for studying both the disease’s etiopathogenesis and the effect of treatments is urgent. The presence of glioma stem-like cells and their role in tumor progression and resistance to therapies need further documentation. Metabolism is now considered as one of the most promising targets in cancer therapies and gliomas are not different. In addition, specific mutations in metabolic pathways have become hallmark of gliomas, such as IDH mutations. There are several drug candidates under development aiming at abnormal metabolic processes and which ones have the best future remains to be seen. Personalized medicine requires not only specific targets, but also determination of who will be the best responder to therapy. CONTINUE READING.....
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.